Clinical practice in management of hydration for lung cancer patients receiving cisplatin-based chemotherapy in Japan: A questionnaire survey

Japanese Journal of Clinical Oncology

Volumn 41, Issue 11, 2011, Pages 1308-1311

  Yamada, Kazuhiko ^a   Yoshida, Tsukasa ^a   Zaizen, Yoshiaki ^a   Okayama, Yusuke ^a   Naito, Yoshiko ^a   Yamashita, Fumie ^a   Takeoka, Hiroaki ^a   Mizoguchi, Yusuke ^a   Yamada, Kazuko ^a   Azuma, Koichi ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Cisplatin; Hydration; Lung cancer; Nephrotoxicity; Questionnaire

Indexed keywords

CISPLATIN; MAGNESIUM; SODIUM CHLORIDE;

ARTICLE; CLINICAL PRACTICE; DIURESIS; HEALTH SURVEY; HUMAN; HYDRATION; JAPAN; LUNG CANCER; MEDICAL SOCIETY; NEPHROTOXICITY; OUTPATIENT; QUESTIONNAIRE; REHYDRATION; TREATMENT PLANNING; URINE FLOW RATE;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; CISPLATIN; COMBINED MODALITY THERAPY; FLUID THERAPY; HUMANS; JAPAN; LUNG NEOPLASMS; PHYSICIAN'S PRACTICE PATTERNS; QUESTIONNAIRES;

EID: 80155170224     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyr145     Document Type: Article

References (8)

1. Cvitkovic E, Spaulding J, Bethune V, Martin J, Whitmore WF. Improvement of cis-dichlorodiammineplatinum (NSC 119875): therapeutic index in an animal model. Cancer 1977;39:1357-61.
2. Wittes RE, Brescia F, Young CW, Magill GB, Golbey RB, Krakoff IH. Combination chemotherapy with cis-diamminedichloroplatinum (II) and bleomycin in tumors of the head and neck. Oncology 1975;32:202-7.
3. Stewart DJ, Dulberg CS, Mikhael NZ, Redmond MD, Montpetit VA, Goel R. Association of cisplatin nephrotoxicity with patient characteristics and cisplatin administration methods. Cancer Chemother Pharmacol 1997;40:293-308.
4. Tiseo M, Martelli O, Mancuso A, Sormani MP, Bruzzi P, Di Salvia R, et al. Short hydration regimen and nephrotoxicity of intermediate to high-dose cisplatin-based chemotherapy for outpatient treatment in lung cancer and mesothelioma. Tumori 2007;93:138-44.
5. Launay-Vacher V, Rey JB, Isnard-Bagnis C, Deray G, Daouphars M. Prevention of cisplatin nephrotoxicity: state of the art and recommendations from the European Society of Clinical Pharmacy Special Interest Group on Cancer Care. Cancer Chemother Pharmacol 2008;61:903-9.
6. Sasaki Y, Tamura T, Eguchi K, Shinkai T, Fujiwara Y, Fukuda M, et al. Pharmacokinetics of (glycolate-0,00)-diammine platinum (II), a new platinum derivative, in comparison with cisplatin and carboplatin. Cancer Chemother Pharmacol 1989;23:243-6.
7. Mor V, Stalker MZ, Gralla R, Scher HI, Cimma C, Park D, et al. Day hospital as an alternative to inpatient care for cancer patients: a random assignment trial. J Clin Epidemiol 1988;41:771-85.
8. Evans TR, Harper CL, Beveridge IG, Wastnage R, Mansi JL. A randomised study to determine whether routine intravenous magnesium supplements are necessary in patients receiving cisplatin chemotherapy with continuous infusion 5-fluorouracil. Eur J Cancer 1995;31A: 174-8.